New Delhi, India, April 3, 2017 – Malaysia’s largest generic pharmaceutical manufacturer, CCM Duopharma Biotech Berhad (CCMD), a subsidiary of Chemical Company of Malaysia Berhad (CCM) has entered into a strategic alliance with India’s Natco Pharma Limited (Natco) and Biocon Limited (Biocon) to offer affordable cancer and insulin therapies in Malaysia.

The signing ceremonies, held earlier today, were witnessed by Malaysian Prime Minister, Datuk Seri Najib Tun Razak who was in India for a five-day official visit.

CCMD and Natco entered into a 15-year partnership via a Consultancy Service Agreement, Technology Transfer Agreement and Supply Agreement to build Malaysia’s first High Active Potent Ingredient Drug (HAPI) manufacturing facility to produce generic oncology medicines.

Through this strategic collaboration , Natco will provide facility design, manufacturing technology transfer as well as active pharmaceutical ingredients (API) to localize the manufacturing of eight cancer products in Malaysia over the next seven years. The project has been proposed for the Entry Point Project (EPP) under the National Key Economic Areas (NKEA) by PEMANDU and will see CCMD allocate a total investment of RM 34.0 million.

The HAPI plant will see CCMD widen its product portfolio capabilities in offering generic oncology medicines to treat breast cancer, lung cancer, colorectal cancer, cervical cancer and blood cancer.

In a separate meeting, CCMD, through its subsidiary CCM Pharmaceuticals Sdn Bhd (CCMP) has formally received the appointment letter from Biocon as the authorized reseller for human insulins in Malaysia following the award of RM300 million contract under the Ministry of Health’s Off Take programme to supply human insulin to all government hospitals and clinics for a period of three years until Dec 1, 2019 to Biocon. This was witnessed by Honourable PM of Malaysia. This is a continuation of CCMD partnership with Biocon as the exclusive marketing and distribution partner in Malaysia and Brunei.

Speaking at the signing ceremonies, YB Dato’ Hajah Normala Abdul Samad, Chairman of CCM said that the collaborations were in line with CCM’s vision to venture into niche therapeutic areas such as oncology, biosimilars and vaccines.

“Strategic alliances with global leaders such as Biocon and Natco, solidifies our position as a key player in the Malaysian pharmaceutical industry. It is also a stepping stone to helping us move up the pharma industry value chain in Asia, strengthening our capabilities from developing generic pharmaceuticals, leveraging the expiry of innovator patents to marketing and distribution.

Through the partnerships, we also hope to offer Malaysians and those in neighboring countries affordable and high quality treatment options in line with our philosophy ‘Enhancing Quality of Life’,” she added.

CCMD is a subsidiary of CCM which is listed on the main market of Bursa Malaysia and is a key player in the pharmaceutical , polymer and chemical industries.